Lv62
2920 积分 2021-06-29 加入
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
3个月前
已完结
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61–20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial
6个月前
已完结
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis
6个月前
已完结
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
7个月前
已完结
Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy
9个月前
已完结
MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer
9个月前
已完结
IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer
9个月前
已完结
The diagnosis and treatment of peripheral lymphedema: 2020 Consensus Document of the International Society of Lymphology
1年前
已完结
Molecular Expression Assays Improve the Prediction of Local and Invasive Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ
1年前
已关闭
ERBB2-Low Breast Cancer—Is It a Fact or Fiction, and Do We Have the Right Assay?
2年前
已完结
皖公网安备34019202002308
